REFERENCES
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
2. Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2018;68:723-50.
3. European Association for the Study of the Liver. European association for the study of the liver. EASL Clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2018;69:182-236.
4. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004;130:417-22.
5. Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med 2014;11:e1001624.
6. Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 2017;11:317-70.
7. Kokudo N, Takemura N, Hasegawa K, Takayama T, Kubo S, et al. Clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update. Hepatol Res 2019;49:1109-13.
8. Tzartzeva K, Obi J, Rich NE, Parikh ND, Marrero JA, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology 2018;154:1706-18.e1.
9. Jeong WK. Surveillance of hepatocellular carcinoma: is only ultrasound enough? Clin Mol Hepatol 2017;23:222-3.
10. Lee CI, Chen LE, Elmore JG. Risk-based breast cancer screening: implications of breast density. Med Clin North Am 2017;101:725-41.
11. Berg WA, Blume JD, Cormack JB, Mendelson EB. Operator dependence of physician-performed whole-breast US: lesion detection and characterization. Radiology 2006;241:355-65.
12. Madjar H, Rickard M, Jellins J, Otto R. IBUS guidelines for the ultrasonic examination of the breast. Eur J Ultrasound 1999;9:99-102.
13. Choi EJ, Lee EH, Kim YM, Chang YW, Lee JH, et al; on the behalf of the Alliance for Breast Cancer Screening in Korea (ABCS-K). Interobserver agreement in breast ultrasound categorization in the Mammography and Ultrasonography Study for Breast Cancer Screening Effectiveness (MUST-BE) trial: results of a preliminary study. Ultrasonography 2019;38:172-80.
15. Simmons O, Fetzer DT, Yokoo T, Marrero JA, Yopp A, et al. Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis. Aliment Pharmacol Ther 2017;45:169-77.
16. Mellinger JL, Shedden K, Winder GS, Tapper E, Adams M, et al. The high burden of alcoholic cirrhosis in privately insured persons in the United States. Hepatology 2018;68:872-82.
17. Perumpail BJ, Khan MA, Yoo ER, Cholankeril G, Kim D, et al. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol 2017;23:8263-76.
18. Schoenberger H, Fetzer D, Yokoo T, Marrero J, Singal AG. Correlates of ultrasound quality for HCC surveillance in patients with cirrhosis. Gastroenterology 2020;158:S-91.
19. Santagostino E, Colombo M, Rivi M, Rumi MG, Rocino A, et al; Study Group of the Association of Italian Hemophilia Centers. A 6-month versus a 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus. Blood 2003;102:78-82.
20. Rich NE, John BV, Parikh ND, Rowe I, Mehta N, et al. Hepatocellular carcinoma demonstrates heterogeneous growth patterns in a multi-center cohort of patients with cirrhosis. Hepatology 2020; doi: 10.1002/hep.31159.
21. Santi V, Trevisani F, Gramenzi A, Grignaschi A, Mirici-Cappa F, et al; Italian Liver Cancer (ITA.LI.CA) Group. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol 2010;53:291-7.
22. Trinchet JC, Chaffaut C, Bourcier V, Degos F, Henrion J, et al; Groupe d’Etude et de Traitement du Carcinome Hépatocellulaire (GRETCH). Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology 2011;54:1987-97.
23. Rich N, Singal AG. Hepatocellular carcinoma tumour markers: current role and expectations. Best Pract Res Clin Gastroenterol 2014;28:843-53.
24. Gopal P, Yopp AC, Waljee AK, Chiang J, Nehra M, et al. Factors that affect accuracy of α-fetoprotein test in detection of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2014;12:870-7.
25. Yang JD, Dai J, Singal AG, Gopal P, Addissie BD, et al. Improved performance of serum alpha-fetoprotein for hepatocellular carcinoma diagnosis in HCV cirrhosis with normal alanine transaminase. Cancer Epidemiol Biomarkers Prev 2017;26:1085-92.
26. Minami T, Tateishi R, Kondo M, Nakagomi R, Fujiwara N, et al. Serum alpha-fetoprotein has high specificity for the early detection of hepatocellular carcinoma after hepatitis C virus eradication in patients. Medicine (Baltimore) 2015;94:e901.
27. Wong GL, Chan HL, Tse YK, Chan HY, Tse CH, et al. On-treatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir. Hepatology 2014;59:986-95.
28. Atiq O, Tiro J, Yopp AC, Muffler A, Marrero JA, et al. An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis. Hepatology 2017;65:1196-205.
29. Berhane S, Toyoda H, Tada T, Kumada T, Kagebayashi C, et al. Role of the GALAD and BALAD-2 serologic models in diagnosis of hepatocellular carcinoma and prediction of survival in patients. Clin Gastroenterol Hepatol 2016;14:875-86.e6.
30. Best J, Bechmann LP, Sowa JP, Sydor S, Dechêne A, et al. GALAD score detects early hepatocellular carcinoma in an international cohort of patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2020;18:728-35.e4.
31. Yang JD, Addissie BD, Mara KC, Harmsen WS, Dai J, et al. GALAD score for hepatocellular carcinoma detection in comparison with liver ultrasound and proposal of GALADUS score. Cancer Epidemiol Biomarkers Prev 2019;28:531-8.
32. Ye Q, Ling S, Zheng S, Xu X. Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA. Mol Cancer 2019;18:114.
33. Ahn JC, Teng PC, Chen PJ, Posadas E, Tseng HR, et al. Detection of circulating tumor cells and their implications as a novel biomarker for diagnosis, prognostication, and therapeutic monitoring in hepatocellular carcinoma. Hepatology 2020; doi: 10.1002/hep.31165.
34. Chalasani NP, Ramasubramanian T, Bruinsma JJ, et al. Combined methlylated DNA and protein markers: An accurate blood-based test for early stage detection of hepatocellular carcinoma, In American Association for the Study of Liver Diseases: Hepatology 2019; 70(S1): 72A-73A. Available from https://aasldpubs.onlinelibrary.wiley.com/doi/10.1002/hep.30940 [Last accessed on 26 Aug 2020].
35. Pocha C, Dieperink E, McMaken KA, Knott A, Thuras P, et al. Surveillance for hepatocellular cancer with ultrasonography vs. computed tomography -- a randomised study. Aliment Pharmacol Ther 2013;38:303-12.
36. Harris PS, Hansen RM, Gray ME, Massoud OI, McGuire BM, et al. Hepatocellular carcinoma surveillance: an evidence-based approach. World J Gastroenterol 2019;25:1550-9.
37. Andersson KL, Salomon JA, Goldie SJ, Chung RT. Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2008;6:1418-24.
38. Kim SY, An J, Lim YS, Han S, Lee JY, et al. MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma. JAMA Oncol 2017;3:456-63.
39. Kim HL, An J, Park JA, Park SH, Lim YS, et al. Magnetic resonance imaging is cost-effective for hepatocellular carcinoma surveillance in high-risk patients with cirrhosis. Hepatology 2019;69:1599-613.
40. Lee JY, Huo EJ, Weinstein S, Santos C, Monto A, et al. Evaluation of an abbreviated screening MRI protocol for patients at risk for hepatocellular carcinoma. Abdom Radiol (NY) 2018;43:1627-33.
41. Khatri G, Pedrosa I, Ananthakrishnan L, de Leon AD, Fetzer DT, et al. Abbreviated-protocol screening MRI vs. complete-protocol diagnostic MRI for detection of hepatocellular carcinoma in patients with cirrhosis: An equivalence study using LI-RADS v2018. J Magn Reson Imaging 2020;51:415-25.
42. Park HJ, Jang HY, Kim SY, Lee SJ, Won HJ, et al. Non-enhanced magnetic resonance imaging as a surveillance tool for hepatocellular carcinoma: comparison with ultrasound. J Hepatol 2020;72:718-24.
43. An C, Kim DY, Choi JY, Han KH, Roh YH, et al. Noncontrast magnetic resonance imaging versus ultrasonography for hepatocellular carcinoma surveillance (MIRACLE-HCC): study protocol for a prospective randomized trial. BMC Cancer 2018;18:915.
44. Kim HA, Kim KA, Choi JI, Lee JM, Lee CH, et al. Comparison of biannual ultrasonography and annual non-contrast liver magnetic resonance imaging as surveillance tools for hepatocellular carcinoma in patients with liver cirrhosis (MAGNUS-HCC): a study protocol. BMC Cancer 2017;17:877.
45. Hoshida Y, Villanueva A, Sangiovanni A, Sole M, Hur C, et al. Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology 2013;144:1024-30.
46. Ioannou GN, Green P, Kerr KF, Berry K. Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification. J Hepatol 2019;71:523-33.
47. Goossens N, Bian CB, Hoshida Y. Tailored algorithms for hepatocellular carcinoma surveillance: Is one-size-fits-all strategy outdated? Curr Hepatol Rep 2017;16:64-71.
48. Singal AG, Yopp A, S Skinner C, Packer M, Lee WM, et al. Utilization of hepatocellular carcinoma surveillance among American patients: a systematic review. J Gen Intern Med 2012;27:861-7.
49. Singal AG, Li X, Tiro J, Kandunoori P, Adams-Huet B, et al. Racial, social, and clinical determinants of hepatocellular carcinoma surveillance. Am J Med 2015;128:90.e1-7.
50. Farvardin S, Patel J, Khambaty M, Yerokun OA, Mok H, et al. Patient-reported barriers are associated with lower hepatocellular carcinoma surveillance rates in patients with cirrhosis. Hepatology 2017;65:875-84.
51. Simmons OL, Feng Y, Parikh ND, Singal AG. Primary care provider practice patterns and barriers to hepatocellular carcinoma surveillance. Clin Gastroenterol Hepatol 2019;17:766-73.
52. Beste LA, Ioannou GN, Yang Y, Chang MF, Ross D, et al. Improved surveillance for hepatocellular carcinoma with a primary care-oriented clinical reminder. Clin Gastroenterol Hepatol 2015;13:172-9.
53. Singal AG, Tiro JA, Murphy CC, Marrero JA, McCallister K, et al. Mailed outreach invitations significantly improve HCC surveillance rates in patients with cirrhosis: a randomized clinical trial. Hepatology 2019;69:121-30.
54. Singal AG, Tiro JA, Marrero JA, McCallister K, Mejias C, et al. Mailed outreach program increases ultrasound screening of patients with cirrhosis for hepatocellular carcinoma. Gastroenterology 2017;152:608-15.e4.
55. Fetzer DT, Rodgers SK, Harris AC, Kono Y, Wasnik AP, et al. Screening and surveillance of hepatocellular carcinoma: an introduction to ultrasound liver imaging reporting and data system. Radiol Clin North Am 2017;55:1197-209.
56. Marrero JA, Hussain HK, Nghiem HV, Umar R, Fontana RJ, et al. Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. Liver Transpl 2005;11:281-9.
57. Tang A, Bashir MR, Corwin MT, Cruite I, Dietrich CF, et al; LI-RADS Evidence Working Group. Evidence supporting LI-RADS major features for CT- and MR imaging-based diagnosis of hepatocellular carcinoma: a systematic review. Radiology 2018;286:29-48.
58. Elsayes KM, Kielar AZ, Chernyak V, Morshid A, Furlan A, et al. LI-RADS: a conceptual and historical review from its beginning to its recent integration into AASLD clinical practice guidance. J Hepatocell Carcinoma 2019;6:49-69.
59. van der Pol CB, Lim CS, Sirlin CB, McGrath TA, Salameh JP, et al. Accuracy of the liver imaging reporting and data system in computed tomography and magnetic resonance image analysis of hepatocellular carcinoma or overall malignancy-a systematic review. Gastroenterology 2019;156:976-86.
60. Shao S, Liang Y, Kuang S, Chen J, Shan Q, et al. Diagnostic performance of LI-RADS version 2018 in differentiating hepatocellular carcinoma from other hepatic malignancies in patients with hepatitis B virus infection. Bosn J Basic Med Sci 2020;20:401-10.
61. Roberts LR, Sirlin CB, Zaiem F, Almasri J, Prokop LJ, et al. Imaging for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Hepatology 2018;67:401-21.
62. Lee YJ, Lee JM, Lee JS, Lee HY, Park BH, et al. Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis. Radiology 2015;275:97-109.
63. Kim JY, Kim MJ, Kim KA, Jeong HT, Park YN. Hyperintense HCC on hepatobiliary phase images of gadoxetic acid-enhanced MRI: correlation with clinical and pathological features. Eur J Radiol 2012;81:3877-82.
64. Sirlin CB, Hussain HK, Jonas E, Kanematsu M, Min Lee J, et al. Consensus report from the 6th International forum for liver MRI using gadoxetic acid. J Magn Reson Imaging 2014;40:516-29.
65. Lu RC, She B, Gao WT, Ji YH, Xu DD, et al. Positron-emission tomography for hepatocellular carcinoma: Current status and future prospects. World J Gastroenterol 2019;25:4682-95.
66. Brix G, Ziegler SI, Bellemann ME, Doll J, Schosser R, et al. Quantification of [(18)F]FDG uptake in the normal liver using dynamic PET: impact and modeling of the dual hepatic blood supply. J Nucl Med 2001;42:1265-73.
67. Wudel LJ Jr., Delbeke D, Morris D, Rice M, Washington MK, et al. The role of [18F]fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma. Am Surg 2003;69:117-24. discussion 124-6
68. Jadvar H. Hepatocellular carcinoma and gastroenteropancreatic neuroendocrine tumors: potential role of other positron emission tomography radiotracers. Semin Nucl Med 2012;42:247-54.
69. Ehman EC, Johnson GB, Villanueva-Meyer JE, Cha S, Leynes AP, et al. PET/MRI: Where might it replace PET/CT? J Magn Reson Imaging 2017;46:1247-62.
70. Hernandez R, Sun H, England CG, Valdovinos HF, Ehlerding EB, et al. CD146-targeted immunoPET and NIRF imaging of hepatocellular carcinoma with a dual-labeled monoclonal antibody. Theranostics 2016;6:1918-33.
71. Jo PC, Jang HJ, Burns PN, Burak KW, Kim TK, et al. Integration of contrast-enhanced US into a multimodality approach to imaging of nodules in a cirrhotic liver: how I do it. Radiology 2017;282:317-31.
72. Kim TK, Noh SY, Wilson SR, Kono Y, Piscaglia F, et al. Contrast-enhanced ultrasound (CEUS) liver imaging reporting and data system (LI-RADS) 2017 - a review of important differences compared to the CT/MRI system. Clin Mol Hepatol 2017;23:280-9.
73. Zhang J, Yu Y, Li Y, Wei L. Diagnostic value of contrast-enhanced ultrasound in hepatocellular carcinoma: a meta-analysis with evidence from 1998 to 2016. Oncotarget 2017;8:75418-26.
74. Bartolotta TV, Taibbi A, Midiri M, Lagalla R. Contrast-enhanced ultrasound of hepatocellular carcinoma: where do we stand? Ultrasonography 2019;38:200-14.
75. Aubé C, Oberti F, Lonjon J, Pageaux G, Seror O, et al; CHIC Group. EASL and AASLD recommendations for the diagnosis of HCC to the test of daily practice. Liver Int 2017;37:1515-25.
76. Vilana R, Forner A, Bianchi L, García-Criado A, Rimola J, et al. Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound. Hepatology 2010;51:2020-9.
77. Chen LD, Xu HX, Xie XY, Xie XH, Xu ZF, et al. Intrahepatic cholangiocarcinoma and hepatocellular carcinoma: differential diagnosis with contrast-enhanced ultrasound. Eur Radiol 2010;20:743-53.
78. Wildner D, Pfeifer L, Goertz RS, Bernatik T, Sturm J, et al. Dynamic contrast-enhanced ultrasound (DCE-US) for the characterization of hepatocellular carcinoma and cholangiocellular carcinoma. Ultraschall Med 2014;35:522-7.
79. Chen LD, Ruan SM, Liang JY, Yang Z, Shen SL, et al. Differentiation of intrahepatic cholangiocarcinoma from hepatocellular carcinoma in high-risk patients: a predictive model using contrast-enhanced ultrasound. World J Gastroenterol 2018;24:3786-98.
80. Shiina S, Teratani T, Obi S, Sato S, Tateishi R, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005;129:122-30.
81. Liu D, Fong DY, Chan AC, Poon RT, Khong PL. Hepatocellular carcinoma: surveillance CT schedule after hepatectomy based on risk stratification. Radiology 2015;274:133-40.
82. Pavel MC, Fuster J. Expansion of the hepatocellular carcinoma Milan criteria in liver transplantation: Future directions. World J Gastroenterol 2018;24:3626-36.
83. Yao FY, Mehta N, Flemming J, Dodge J, Hameed B, et al. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology 2015;61:1968-77.
84. Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NL, et al. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant 2007;7:2587-96.
85. Kardashian A, Florman SS, Haydel B, Ruiz RM, Klintmalm GB, et al. Liver transplantation outcomes in a U.S. multicenter cohort of 789 patients with hepatocellular carcinoma presenting beyond milan criteria. Hepatology 2020; doi: 10.1002/hep.31210.
86. Mehta N, Heimbach J, Harnois DM, Sapisochin G, Dodge JL, et al. Validation of a risk estimation of tumor recurrence after transplant (RETREAT) score for hepatocellular carcinoma recurrence after liver transplant. JAMA Oncol 2017;3:493-500.
87. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
88. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, et al. Clinical management of hepatocellular carcinoma. conclusions of the barcelona-2000 EASL conference. J Hepatol 2001;35:421-30.
89. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30:52-60.
90. Gillmore R, Stuart S, Kirkwood A, Hameeduddin A, Woodward N, et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol 2011;55:1309-16.
91. Fournier L, Ammari S, Thiam R, Cuénod CA. Imaging criteria for assessing tumour response: RECIST, mRECIST, Cheson. Diagn Interv Imaging 2014;95:689-703.
92. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
93. Cheng A, Kang Y, Chen Z, Tsao C, Qin S, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
94. Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med 2018;379:54-63.
95. Bruix J, Qin S, Merle P, Granito A, Huang Y, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;389:56-66.
96. Kudo M, Finn RS, Qin S, Han K, Ikeda K, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018;391:1163-73.
97. Edeline J, Boucher E, Rolland Y, Vauléon E, Pracht M, et al. Comparison of tumor response by response evaluation criteria in solid tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer 2012;118:147-56.
98. Kudo M, Finn RS, Qin S, Han K, Ikeda K, et al. Analysis of survival and objective response (OR) in patients with hepatocellular carcinoma in a phase III study of lenvatinib (REFLECT). JCO 2019;37:186.
99. Llovet JM, Montal R, Villanueva A. Randomized trials and endpoints in advanced HCC: role of PFS as a surrogate of survival. J Hepatol 2019;70:1262-77.
100. Bangaru S, Marrero JA, Singal AG. Review article: new therapeutic interventions for advanced hepatocellular carcinoma. Aliment Pharmacol Ther 2020;51:78-89.
101. El-khoueiry AB, Melero I, Yau TC, Crocenzi TS, Kudo M, et al. Impact of antitumor activity on survival outcomes, and nonconventional benefit, with nivolumab (NIVO) in patients with advanced hepatocellular carcinoma (aHCC): Subanalyses of CheckMate-040. JCO 2018;36:475.
102. Grierson P, Crites D, Ruzinova MB, Yano M, Lim KH. Distinct clinical and magnetic resonance features of metastatic hepatocellular carcinoma treated with pembrolizumab: a case report of late response after pseudoprogression. Hepatol Commun 2018;2:148-51.
103. Wong DJ, Lee J, Choo SP, Thng CH, Hennedige T. Hyperprogressive disease in hepatocellular carcinoma with immune checkpoint inhibitor use: a case series. Immunotherapy 2019;11:167-75.
104. Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 2017;18:e143-52.
105. Henze J, Maintz D, Persigehl T. RECIST 1.1, irRECIST 1.1, and mRECIST: how to do. Curr Radiol Rep 2016;4.
106. Edeline J, Karwal M, Zhu AX, Finn RS, Cattan S, et al. RECIST v1.1 and irRECIST outcomes in advanced HCC treated with pembrolizumab (pembro). JCO 2020;38:528.
107. Zwanenburg A, Vallières M, Abdalah MA, Aerts HJWL, Andrearczyk V, et al. The image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping. Radiology 2020;295:328-38.
108. Kim Y, Furlan A, Borhani AA, Bae KT. Computer-aided diagnosis program for classifying the risk of hepatocellular carcinoma on MR images following liver imaging reporting and data system (LI-RADS). J Magn Reson Imaging 2018;47:710-22.
